← All trials
NCT06767748
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2025
- Primary completion
- Feb 7, 2026
- Completion date
- Feb 28, 2026
- First posted
- Jan 10, 2025
- Last posted
- Jan 10, 2025
- Enrollment
- 620
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gan and Lee Pharmaceuticals, USALead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.